Artivion 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Artivion reported 3rd quarter 2026 revenue of $123.8 million, up 9% year over year on an adjusted constant currency basis; excluding Perclot, growth was 8%.
- Adjusted EBITDA declined approximately 8%, from $24.6 million to $22.5 million, and adjusted EBITDA margin was 18.2%, down approximately 350 basis points from the prior year.
- StentGraft revenue grew 12% and Onyx revenue grew 13% on a constant currency basis; tissue processing revenue declined 0.3%, and BioGlue revenue increased 0.1%.
- Revenue increased 8% in North America, 11% in EMEA, 8% in Asia Pacific, and 5% in Latin America compared with the 3rd quarter of 2025.
- Gross margin was 61.4%, down from 65.6% in the 3rd quarter of 2025, as favorable pricing was more than offset by unfavorable mix and higher costs at the Onyx and Nexus manufacturing facilities.
- Free cash flow was negative $17.6 million, compared with positive $17.7 million in the 3rd quarter of 2025; it included a $13.3 million operating cash classification for part of the AMDS PMA milestone payment and approximately $2 million of EndoSpan-related integration expenses.
- As of September 30th, 2026, Artivion had approximately $48.4 million in cash and $363.8 million in debt, net of $6.2 million of unamortized loan origination costs; its net leverage ratio was 3.5.
- Other revenue grew 93% year over year, driven by Percloth; the transitional manufacturing and supply agreement with Baxter is expected to expire in February of 2027, with the final purchase expected in December of this year.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Reminder, this conference is being recorded. It is now my pleasure to introduce your host, Brian Johnston, from the Gilmartin Group. Thank you. You may begin.
Good afternoon, and thank you for joining the call today. Joining me from Artivion's management team are Pat Mackin, CEO, and Lance Berry, COO and CFO. Before we begin, I would like to make the following statements to comply with the Safe Harbor requirements of the Private Securities Litigation Reform Act of 1995. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company's or management's intentions, hopes, beliefs, expectations, or predictions of the future. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from these forward-looking statements.
Additional information concerning certain risks and uncertainties that may impact these forward-looking statements is contained from time to time in the company's SEC filings, as well as the press release that was issued earlier today. You can also find a brief presentation with details highlighted on today's call on the Investor Relations section of the Artivion website. Lastly, I'd like to remind you to please refer to our press release published earlier today for information regarding our non-GAAP results, including a reconciliation of these results to our GAAP results. Unless otherwise stated, all of our comments in today's call will be using our non-GAAP results. Additionally, all percentage changes discussed will be on a year-over-year basis. Revenue growth rates will be the adjusted constant currency rates, and expenses as percentages of sales will be based on adjusted revenues. With that, I'll turn it over to Artivion CEO, Pat Mackin.
Hey, thanks, Brian, and good afternoon, everybody. In the third quarter, we delivered total constant currency revenue growth of 9% and adjusted EBITDA decline of 8% year-over-year. These results reflect continued execution of our strategy designed to deliver long-term profitable growth through an expanding and clinically differentiated product portfolio. From a product category perspective, stent graft revenues grew 12% on a constant currency basis in the third quarter compared to the same period last year. This performance is consistent with the growth rate we report in Q2, and notably came against a tougher AMDS prior year comparison this quarter. On AMDS, the number of U.S. implants increased from the second quarter, which we believe reflects the impact of our recent PMA approval and our efforts to drive adoption of this new technology.
We continue to view implant increases as the most important indicator of AMDS adoption, given it reflects the real-world use and the user experience that will drive growth in the long term. Meanwhile, U.S. AMDS set sales remain challenged. We view this dynamic as administrative and transient. We remain confident that the set sales will build as the benefits of our initiatives aimed at mitigating the barriers associated with the upfront $100,000 investment for starter sets takes hold. Now for a brief update on NEXUS. We believe our preparations for U.S. commercial launch early next year are progressing well. For the remainder of 2026, our focus will remain on expanding manufacturing capacity and building inventory, working through value analysis committee processes, augmenting our U.S. sales team, and preparing for broader surgeon training.
Interest across the clinical community has continued to build, and we look forward to conducting our first surgeon training event in December. In the meantime, we are continuing to support some U.S. cases on a limited basis. Feedback from surgeons using the technology has been excellent, and we believe there is a significant demand for NEXUS ahead of the U.S. launch, which is expected in January of 2027. We look forward to providing additional updates on launch timing and readiness as we get closer. Ultimately, we see our comprehensive stent graft portfolio as foundational component of our growth strategy. We believe our competitive advantages and surgeon demand will drive greater sustainable adoption and utilization over the medium term. Turning to On-X. Our third quarter On-X revenue grew 13% year-over-year on a constant currency basis.
This performance was driven by continued mid-teens revenue growth in the U.S., partially offset by lower growth internationally, which we view as a normal quarterly variation. Importantly, we exited the quarter in a strong supply position as a result of the investments we have made in our Austin manufacturing facility. We believe that puts us in a stronger position to meet demand globally as we close the year and enter 2027 with a product that we believe is the best aortic valve on the market for patients under the age of 65. Tissue processing revenue declined 0.3% year-over-year on a constant currency basis due to a difficult prior year comp, but was ahead of our expectations for the quarter. Regarding BioGlue, revenues increased modestly on a constant currency basis compared to the same period last year.
As we have discussed during our previous calls this year, this product line carries a meaningful amount of stocking distributor orders, which creates some normal quarter-to-quarter variability. Importantly, our long-term outlook for BioGlue remains unchanged. Lastly, revenue in our other category grew 93% year-over-year, driven by PerClot. As we have previously noted, our transitional manufacturing and supply agreement with Baxter will expire in February of 2027, and we expect the final purchase to be made in December of this year. Overall, the PerClot transaction has been a significant positive, as it allowed us to turn a non-strategic asset into cash. Although it has taken us longer than we would have hoped to get to this point, we are glad to be reaching the end of this transition services and to be able to completely focus on our ongoing business.
Turning to our pipeline, we continue to make progress on the ARTIZEN clinical trial for our Arcevo LSA product. We now have 56 patients enrolled in that trial, which is a non-randomized clinical trial, up to 132 patients in the U.S. and Europe, and up to 30 centers for the treatment of aortic dissection and aneurysm in the aortic arch. We continue to anticipate completing enrollment in mid-2027. We are optimistic that the trial will be successful based in part on the positive clinical results from our current generation frozen elephant trunk called the E-vita Open NEO, which we sell outside the U.S. Following a one-year period of follow-up and assuming the trial meets its endpoints, we anticipate FDA approval for our Arcevo LSA in 2029, unlocking an incremental $80 million opportunity in the U.S. market.
In conclusion, we continue to advance our overall strategy in the third quarter while generating solid financial and operational results. Stent grafts grew 12% for the second consecutive quarter. NEXUS launch preparations are on track. We exited the quarter with a much stronger supply position on On-X. We continue to believe the fundamentals that underpin our growth strategy remain strong, a comprehensive clinically differentiated portfolio, a focused commercial organization, and a pipeline that stands to expand our total addressable market over time. With that, I'll now turn the call over to Lance.
Thanks, Pat, and good afternoon, everyone. Before I begin, I would like to remind you to please refer to our press release published earlier today for information regarding our non-GAAP results, including a reconciliation of these results to our GAAP results. Additionally, all percentage changes discussed will be on a year-over-year basis, and revenue growth rates will be in constant currency unless otherwise noted. Total revenues were $123.8 million for the third quarter of 2026, up 9% compared to Q3 of 2025. PerClot had an approximately 1 percentage point favorable impact to our growth rate. Excluding PerClot, our constant currency growth rate was 8%. Meanwhile, adjusted EBITDA decreased approximately 8% from $24.6 million to $22.5 million in the third quarter of 2026.
Adjusted EBITDA margin was 18.2% in the third quarter of 2026, an approximately 350 basis point decrease from the prior year, primarily driven by costs associated with the Endospan business and gross margin, which was impacted by mix and investments in the On-X and NEXUS manufacturing facilities. From a product line perspective, stent graft revenues increased 12%, On-X grew 13%, tissue processing revenues decreased 0.3%, and BioGlue revenues increased 0.1% in the third quarter of 2026. On a regional basis, revenues in North America increased 8%, EMEA increased 11%, Asia Pacific increased 8%, and Latin America increased 5%, all compared to the third quarter of 2025.
Q3 gross margins were 61.4%, a decrease from 65.6% in the third quarter of 2025, as favorable pricing was more than offset by unfavorable mix and some higher costs in our On-X and NEXUS manufacturing facilities as we incur early costs associated with ramping production. General administrative and marketing expenses in the third quarter were $63.2 million compared to $57.3 million in the third quarter of 2025. Non-GAAP general administrative and marketing expenses were $57.7 million, or 46.6% of sales in the third quarter, compared to $53.6 million, or 47.3% of sales in the third quarter of 2025. Approximately 120 basis points of year-over-year improvement was driven through leveraging existing infrastructure while absorbing costs associated with the acquired Endospan business, and approximately 30 basis points of leverage from stock-based compensation, which were partially offset by approximately 80 basis points of deleverage from increased amortization expense following the acquisition of Endospan.
R&D expenses for the third quarter were $9.8 million, or 7.9% of sales, compared to $8.1 million, or 7.1% of sales in the third quarter of 2025. Interest expense net of interest income was $8.4 million as compared to $5.9 million in the prior year. Other income and expense this quarter included foreign currency translation losses of approximately $0.6 million. Free cash flow was negative $17.6 million in the third quarter of 2026 as compared to positive $17.7 million in the third quarter of 2025. This quarter's free cash flow was unfavorably impacted by $13.3 million for a portion of the AMDS PMA milestone payment that was required to be classified as operating cash and approximately $2 million of Endospan-related integration expenses.
Excluding these items, remaining free cash flow was relatively neutral as anticipated, as we continue to invest in the On-X manufacturing facility and incur costs to run the acquired Endospan business and to prepare for a U.S. NEXUS launch. As of September 30, 2026, we had approximately $48.4 million in cash and $363.8 million in debt, net of $6.2 million of unamortized loan origination cost. At the end of the third quarter, our net leverage ratio was 3.5, reflecting the impact of the recent $25 million AMDS PMA milestone payment in July. Now for our outlook for 2026. We are narrowing our expectation for adjusted constant currency growth to now be between 8%-10% for the full year 2026, representing a reported revenue range of $484 million-$492 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
